Literature DB >> 7927490

Chlorpromazine specifically inhibits peripheral and brain TNF production, and up-regulates IL-10 production, in mice.

M Mengozzi1, G Fantuzzi, R Faggioni, A Marchant, M Goldman, S Orencole, B D Clark, M Sironi, F Benigni, P Ghezzi.   

Abstract

We have previously shown that chlorpromazine (CPZ) inhibits tumour necrosis factor (TNF) production and protects against endotoxic shock in mice. In this paper we investigated the effect of pretreatment with CPZ, 4 mg/kg i.p. 30 min before, compared with dexamethasone (DEX; 3 mg/kg) on the induction of other endotoxin (lipopolysaccharide; LPS)-induced cytokines in the serum of mice, i.e. interleukin-1 alpha (IL-1 alpha), IL-6 and IL-10, and TNF. We also studied the effect of CPZ on serum and spleen-associated TNF. Both DEX and CPZ inhibited TNF production, whereas induction of IL-1 and IL-6 was inhibited by DEX but not by CPZ. DEX did not affect IL-10, while CPZ potentiated its induction. CPZ also inhibited spleen-associated TNF induction in LPS-treated mice, suggesting an effect on the synthesis of TNF. CPZ inhibited TNF induction by Gram-positive bacteria (heat-killed Staphylococcus epidermidis) and by anti-CD3 monoclonal antibodies. Intraperitoneal administration of CPZ also inhibited the induction of brain-associated TNF induced by intra-cerebroventricular injection of LPS. Therefore, CPZ is a more specific inhibitor of TNF production than DEX; in particular, CPZ increased the induction of IL-10, which is a 'protective' cytokine known to inhibit LPS toxicity and TNF production. CPZ inhibited TNF production in vivo, irrespective of the TNF stimulus used to induce TNF. Finally, CPZ did not induce the 'rebound' effect of DEX that, when given 24 hr before LPS, potentiates TNF production, but it did inhibit TNF production after 24 hr.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7927490      PMCID: PMC1414809     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  18 in total

1.  [Comparative action of promethazine, chlorpromazine and cortisone in mice receiving fatal doses of a bacterial endotoxin].

Authors:  L CHEDID
Journal:  C R Seances Soc Biol Fil       Date:  1954-06

2.  IL-1 stimulates IL-6 production in endothelial cells.

Authors:  M Sironi; F Breviario; P Proserpio; A Biondi; A Vecchi; J Van Damme; E Dejana; A Mantovani
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

3.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.

Authors:  K J Tracey; Y Fong; D G Hesse; K R Manogue; A T Lee; G C Kuo; S F Lowry; A Cerami
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

4.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

5.  Pharmacological activities of chlorpromazine involved in the inhibition of tumour necrosis factor production in vivo in mice.

Authors:  R Bertini; S Garattini; R Delgado; P Ghezzi
Journal:  Immunology       Date:  1993-06       Impact factor: 7.397

6.  Determination of chlorpromazine in the blood and brain of mice by high performance liquid chromatography combined with electrochemical detection.

Authors:  S Shibanoki; Y Gotoh; K Ishikawa
Journal:  Jpn J Pharmacol       Date:  1984-06

7.  The role of cytokines in the generation of inflammation and tissue damage in experimental gram-positive meningitis.

Authors:  K Saukkonen; S Sande; C Cioffe; S Wolpe; B Sherry; A Cerami; E Tuomanen
Journal:  J Exp Med       Date:  1990-02-01       Impact factor: 14.307

8.  Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock.

Authors:  M Gadina; R Bertini; M Mengozzi; M Zandalasini; A Mantovani; P Ghezzi
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307

9.  Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia.

Authors:  C Gérard; C Bruyns; A Marchant; D Abramowicz; P Vandenabeele; A Delvaux; W Fiers; M Goldman; T Velu
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

10.  In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporin A.

Authors:  P Durez; D Abramowicz; C Gérard; M Van Mechelen; Z Amraoui; C Dubois; O Leo; T Velu; M Goldman
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

View more
  14 in total

1.  Plasma cytokine response to surgical stress in schizophrenic patients.

Authors:  A Kudoh; T Sakai; H Ishihara; A Matsuki
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

2.  The effects of dexamethasone and chlorpromazine on tumour necrosis factor-alpha, interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-10 in human volunteers.

Authors:  M W Bleeker; M G Netea; B J Kullberg; J Van der Ven-Jongekrijg; J W Van der Meer
Journal:  Immunology       Date:  1997-08       Impact factor: 7.397

3.  Resistance to lipopolysaccharide mediated by the Yersinia pestis V antigen-polyhistidine fusion peptide: amplification of interleukin-10.

Authors:  Y A Nedialkov; V L Motin; R R Brubaker
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

4.  Chlorpromazine, a Clinically Approved Drug, Inhibits SARS-CoV-2 Nucleocapsid-Mediated Induction of IL-6 in Human Monocytes.

Authors:  Iwona Karwaciak; Kaja Karaś; Anna Sałkowska; Joanna Pastwińska; Marcin Ratajewski
Journal:  Molecules       Date:  2022-06-07       Impact factor: 4.927

5.  Role of Ca/CaN/NFAT signaling in IL-4 expression by splenic lymphocytes exposed to phthalate (2-ethylhexyl) ester in spleen lymphocytes.

Authors:  Xiucong Pei; Zhiwen Duan; Mingyue Ma; Yuming Zhang; Li Guo
Journal:  Mol Biol Rep       Date:  2014-01-14       Impact factor: 2.316

6.  Ciliary neurotrophic factor inhibits brain and peripheral tumor necrosis factor production and, when coadministered with its soluble receptor, protects mice from lipopolysaccharide toxicity.

Authors:  F Benigni; P Villa; M T Demitri; S Sacco; J D Sipe; L Lagunowich; N Panayotatos; P Ghezzi
Journal:  Mol Med       Date:  1995-07       Impact factor: 6.354

7.  Pattern of cytokines and pharmacomodulation in sepsis induced by cecal ligation and puncture compared with that induced by endotoxin.

Authors:  P Villa; G Sartor; M Angelini; M Sironi; M Conni; P Gnocchi; A M Isetta; G Grau; W Buurman; L J van Tits
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

8.  Association Between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: An Observational Multicenter Study.

Authors:  Nicolas Hoertel; Marina Sánchez-Rico; Erich Gulbins; Johannes Kornhuber; Alexander Carpinteiro; Eric J Lenze; Angela M Reiersen; Miriam Abellán; Pedro de la Muela; Raphaël Vernet; Carlos Blanco; Céline Cougoule; Nathanaël Beeker; Antoine Neuraz; Philip Gorwood; Jesús M Alvarado; Pierre Meneton; Frédéric Limosin
Journal:  Clin Pharmacol Ther       Date:  2021-07-02       Impact factor: 6.903

9.  The value of interleukin 6 as a peripheral diagnostic marker in schizophrenia.

Authors:  Kayla A Chase; Jackson J Cone; Cherise Rosen; Rajiv P Sharma
Journal:  BMC Psychiatry       Date:  2016-05-20       Impact factor: 3.630

10.  Could the antipsychotic chlorpromazine be a potential treatment for SARS-CoV-2?

Authors:  B Nobile; M Durand; P Courtet; P Van de Perre; N Nagot; J P Molès; E Olié
Journal:  Schizophr Res       Date:  2020-07-25       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.